Clinical Trial Update: BCMA/CD3 BsAb Therapy for POEMS Syndrome [Phase 2]

View source ↗

Summary

Phase 2 clinical trial testing a BCMA/CD3 bispecific antibody therapy for POEMS syndrome; the study is not yet recruiting.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Poems Syndrome

Drugs mentioned

• BCMA/CD3 bispecific antibody therapy

Snippet

Sponsor: Institute of Hematology & Blood Diseases Hospital, China | Conditions: POEMS Syndrome | Phase 2 | Status: NOT_YET_RECRUITING